<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04410315</url>
  </required_header>
  <id_info>
    <org_study_id>Prosp.Laktat.Tumorkraniotomi</org_study_id>
    <nct_id>NCT04410315</nct_id>
  </id_info>
  <brief_title>Hyperlactatemia During and After Tumorcraniotomy</brief_title>
  <official_title>Elevated Serum-lactate in Patients With Brain Tumor During and After Elective Craniotomy: an Observational Clinical Study of Postoperative Patient Outcome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the association between hyperlactatemia and neurological
      disability, length-of-stay and mortality in patients who undergo tumorcraniotomy. The risk
      factors that induce lactat accumulation will also be explored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperlactatemia is a frequent occurrence in brain tumor surgery. The existing studies,
      however, are all retrospective, reporting varying effects on clinical outcome. One study
      reported new neurological deficitis, some found an association with extended hospital stay,
      while others found no association with outcome. It is therefore important to conduct a
      prospective study of hyperlactatemia in this patientgroup.

      Participants in this study will follow the standard treatment protocol for tumorcraniotomy,
      aside from 2-3 additional, perioperative blodgas analyses and 2 standardized measurements of
      neurological disability.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 6, 2020</start_date>
  <completion_date type="Anticipated">May 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological disability</measure>
    <time_frame>Change from baseline mRS at 30 days after surgery</time_frame>
    <description>Modified Rankin Scale (Scoring 0-6, high scores meaning worse outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1 year</time_frame>
    <description>In days from admission to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>After 30 days, 6 months and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Hyperlactatemia</condition>
  <condition>Brain Tumor</condition>
  <condition>Surgery</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Tumorcraniotomy patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum-lactate &lt; 2,2 mmol/L</intervention_name>
    <description>Bloodgas analysis every hour from start surgery until recovery ward discharge</description>
    <arm_group_label>Tumorcraniotomy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum-lactate &gt;/= 2,2 mmol/L</intervention_name>
    <description>Bloodgas analysis every hour from start surgery until recovery ward discharge</description>
    <arm_group_label>Tumorcraniotomy patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing tumorcraniotomy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18 years

          -  Must undergo elective tumor craniotomy

          -  Understand oral and written Danish

        Exclusion Criteria:

          -  Adults with incapacity

          -  Stereotactic biopsy

          -  Lack of informed and signed consent to participate in study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neuroanesthesiology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Alexandra Vassilieva</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Hyperlactatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

